Japan Drug Registration: Waiver of Japanese Phase 1 Studies in Multi-regional Clinical Trials
In December 2023, Japan introduced important regulatory changes that significantly reshape global drug development strategies. Under new guidance issued by Japan’s Ministry of Health, Labour and Welfare (MHLW), drug developers will now be allowed to include Japanese subjects in their multi-regional clinical... Read More